Skip to content

Medical emergency? What to do

Consumer group awards 'bitter pills' to drugmakers

3-RXPublished April 28, 20062 min read

Key points

  • It's one of the most recognizable logos in drug advertising: a light green luna moth that floats across the television screen during advertisements for Sepracor Inc.'s sleeping pill Lunesta.
  • The Prescription Access Litigation Project (PAL), a coalition of 118 state, local and national consumer health advocacy groups, gave the five what it calls a "bitter pill" award.
  • "Drug ads expand the market for newer drugs far beyond those patients that actually need them, interfere with the doctor-patient relationship, and perpetuate the myth that 'there's a pill for every ill' and that 'newer is better,'" it said in a statement.
  • According to the trade publication Medical Marketing and Media, Sepracor spent $215.1 million on Lunesta advertising in 2005, second only to the amount AstraZeneca spent on its "purple pill" Nexium.

It's one of the most recognizable logos in drug advertising: a light green luna moth that floats across the television screen during advertisements for Sepracor Inc.'s sleeping pill Lunesta.

A national health and consumer advocacy group on Wednesday singled out ads by Sepracor and four other drugmakers as evidence of overly aggressive direct marketing by pharmaceutical companies to consumers.

The Prescription Access Litigation Project (PAL), a coalition of 118 state, local and national consumer health advocacy groups, gave the five what it calls a "bitter pill" award.

The awards were created in 2005 to highlight the potential problems of excessive marketing, particularly direct-to-consumer advertising which skirts the input of doctors, the group said.

"Drug ads expand the market for newer drugs far beyond those patients that actually need them, interfere with the doctor-patient relationship, and perpetuate the myth that 'there's a pill for every ill' and that 'newer is better,'" it said in a statement.

The list also includes Pfizer Inc.'s cholesterol-lowering treatment Lipitor; Sanofi-Aventis' sleep drug Ambien; Eli Lilly and Co.'s Strattera for attention deficit hyperactivity disorder; and AstraZeneca Plc's cholesterol drug Crestor.

According to the trade publication Medical Marketing and Media, Sepracor spent $215.1 million on Lunesta advertising in 2005, second only to the amount AstraZeneca spent on its "purple pill" Nexium. Pfizer's spending on Lipitor, the world's biggest-selling drug, was a mere $93.4 million by comparison.

While a company like Pfizer, the world's biggest drug maker, is expected to spend big on consumer advertising, a company like Sepracor, which has a market capitalization of just $4.6 billion to Pfizer's $182 billion, isn't, said Alex Sugerman-Brozan, director of PAL.

"It's very unusual," he said. "Sepracor has shot up the chart in spending. We'll see in 2006 whether they've overextended themselves."

A spokesman for Sepracor was not immediately available for comment.

PAL also gave an award to The Pharmaceutical Research and Manufacturers of America (PhRMA), which represent the pharmaceuticals industry, for not enforcing the direct-to-consumer advertising guidelines it issued last year.

PhRMA said in a statement that the guidelines "are beginning to work, and we believe they should be given additional time to function more robustly."

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.